Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This was an open-label, single-dose study to assess the safety, tolerability, and
absorption/distribution kinetics of a single 100 µg dose of fentanyl sublingual spray in
opioid-tolerant cancer subjects, with or without oral mucositis.